Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Detection of Mosaic Trisomy 9 Missed by Conventional Cytogenetics Using SNP-array and Fluorescence in Situ Hybridization

Detectionof Fetal Trisomy 8 Mosaicism with Cell-free Fetal DNA in Maternal Plasma

Prenatal Diagnosis of Trisomy 8 Mosaicism, Initially Identified by Cffdna Screening

Using SNP array to identify aneuploidy and segmental imbalance in translocation carriers.

Case report: Detection of fetal trisomy 9 mosaicism by multiple genetic testing methods: Report of two cases

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

A method for noninvasive detection of fetal large deletions/duplications by low coverage massively parallel sequencing.

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

[Evaluation of Detection and Analysis of Chromosome 22q11.2 Microdeletion by Multiple Ligation-Dependent Probe Amplification Assay].

[Mosaic trisomy 20: discrepancy between cyto-and molecular genetic technologies in prenatal diagnosis]

Birth of A Child with Trisomy 9 Mosaicism Syndrome Associated with Paternal Isodisomy 9: Case of A Positive Noninvasive Prenatal Test Result Unconfirmed by Invasive Prenatal Diagnosis

Case Report: Prenatal Diagnosis of Fetal Tetrasomy 9p Initially Identified by Non-Invasive Prenatal Testing

First Case Report of Maternal Mosaic Tetrasomy 9p Incidentally Detected on Non-Invasive Prenatal Testing

[Application of Single Nucleotide Polymorphism Microarray in Clinical Diagnosis of Intellectual Disability or Retardation].

Detection of fetal duplication 16p11.2q12.1 by next-generation sequencing of maternal plasma and invasive diagnosis.

Prenatal diagnosis of mosaic trisomy 18 and maternal uniparental disomy 18 by amniocentesis in a pregnancy associated with cytogenetic discrepancy in various tissues and a favorable fetal outcome

[Single Nucleotide Polymorphism Microarray in Prenatal Diagnosis of Fetuses with Absent Nasal Bone].

Case Report: Identification of Maternal Low-Level Mosaicism in the Dystrophin Gene by Droplet Digital Polymerase Chain Reaction

Characteristics and mechanisms of mosaicism in prenatal diagnosis cases by application of SNP array

Analysis of Xp22.31q27.1 Region Variation Detection based on SNP Array Technology

Detection of Aneuploidy from Single Cells by Array-Comparative Genetic Hybridization